Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

W. Deenik; B. van der Holt; G.E.G. Verhoef; W.M Smit; MJ Kersten; H.C. Kluin-Nelemans; L.F. Verdonck; A. Ferrant; A.V.M.B. Schattenberg; J.J.W.M. Janssen; P. Sonneveld; M. van Marwijk-Kooy; S. Wittebol; R. Willemze; P.W. Wijermans; P.H.M Westveer; H.B. Beverloo; P. Valk; B. Lowenberg; G.J. Ossenkoppele; J.J. Cornelissen

Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

Translated title of the contribution: Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

W. Deenik
, B. van der Holt
, G.E.G. Verhoef
, W.M Smit
, MJ Kersten
, H.C. Kluin-Nelemans
, L.F. Verdonck
, A. Ferrant
, A.V.M.B. Schattenberg
, J.J.W.M. Janssen
, P. Sonneveld
, M. van Marwijk-Kooy
, S. Wittebol
, R. Willemze
, P.W. Wijermans
, P.H.M Westveer
, H.B. Beverloo
, P. Valk
, B. Lowenberg
, G.J. Ossenkoppele

J.J. Cornelissen

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
Original language	Undefined/Unknown
Pages (from-to)	2581-2588
Number of pages	8
Journal	Blood
Volume	111
Issue number	5
Publication status	Published - 2008

Cite this

Deenik, W., van der Holt, B., Verhoef, G. E. G., Smit, W. M., Kersten, MJ., Kluin-Nelemans, H. C., Verdonck, L. F., Ferrant, A., Schattenberg, A. V. M. B., Janssen, J. J. W. M., Sonneveld, P., van Marwijk-Kooy, M., Wittebol, S., Willemze, R., Wijermans, P. W., Westveer, P. H. M., Beverloo, H. B., Valk, P., Lowenberg, B., ... Cornelissen, J. J. (2008). Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood, 111(5), 2581-2588.

@article{28f6dba4ce7047f89371e9d186ed55a4,

title = "Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia",

author = "W. Deenik and \{van der Holt\}, B. and G.E.G. Verhoef and W.M Smit and MJ Kersten and H.C. Kluin-Nelemans and L.F. Verdonck and A. Ferrant and A.V.M.B. Schattenberg and J.J.W.M. Janssen and P. Sonneveld and \{van Marwijk-Kooy\}, M. and S. Wittebol and R. Willemze and P.W. Wijermans and P.H.M Westveer and H.B. Beverloo and P. Valk and B. Lowenberg and G.J. Ossenkoppele and J.J. Cornelissen",

year = "2008",

language = "Undefined/Unknown",

volume = "111",

pages = "2581--2588",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "5",

}

Deenik, W, van der Holt, B, Verhoef, GEG, Smit, WM, Kersten, MJ, Kluin-Nelemans, HC, Verdonck, LF, Ferrant, A, Schattenberg, AVMB, Janssen, JJWM, Sonneveld, P, van Marwijk-Kooy, M, Wittebol, S, Willemze, R, Wijermans, PW, Westveer, PHM, Beverloo, HB, Valk, P, Lowenberg, B, Ossenkoppele, GJ & Cornelissen, JJ 2008, 'Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia', Blood, vol. 111, no. 5, pp. 2581-2588.

TY - JOUR

T1 - Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

AU - Deenik, W.

AU - van der Holt, B.

AU - Verhoef, G.E.G.

AU - Smit, W.M

AU - Kersten, MJ

AU - Kluin-Nelemans, H.C.

AU - Verdonck, L.F.

AU - Ferrant, A.

AU - Schattenberg, A.V.M.B.

AU - Janssen, J.J.W.M.

AU - Sonneveld, P.

AU - van Marwijk-Kooy, M.

AU - Wittebol, S.

AU - Willemze, R.

AU - Wijermans, P.W.

AU - Westveer, P.H.M

AU - Beverloo, H.B.

AU - Valk, P.

AU - Lowenberg, B.

AU - Ossenkoppele, G.J.

AU - Cornelissen, J.J.

PY - 2008

Y1 - 2008

M3 - Article

SN - 0006-4971

VL - 111

SP - 2581

EP - 2588

JO - Blood

JF - Blood

IS - 5

ER -